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ABSTRACT 
Martel, Christopher, Development of a Mass Detection Technique to Detect Intakes of 
Radioactive Material and their Resulting Radiation Exposures Following a Large-Scale 
Radiological Release. Medical Health Physics, May, 2019, Worcester Polytechnic Institute, 
Worcester, Massachusetts. 
Large-scale radiological accidents have resulted in intakes of radioactive materials by 
members of the public and occupational radiation workers.  However, current methods to 
evaluate intakes are designed for small numbers of individuals and cannot be easily scaled 
for large populations as has occurred.  A proposed method for high throughput volumes of 
people to identify and quantify intakes of radioactive material through urine radiobioassay is 
described.  MATERIALS AND METHODS: The MCNP V6.0 software code was used to model 
the General Electric Hawkeye V3 Gamma Camera for gamma ray efficiency.  Technitium-99m 
was used to validate the model. The model was used to calculate detection efficiencies and 
minimum detectable doses for Cobalt-60, Iodine-131, Cesium-137/Barium-137m and Iridium-
192. RESULTS:  Differences of 8% were observed between measurements of the detection 
efficiency for Technitium-99m and the MCNP modeled detection efficiency (11.1% vs. 12.0%, 
respectively).  Calculations showed that a dose of 20 mSv could be detected using urine 
radiobioassay in 6, 3, 2, and 20 days post incident for Type F intakes of Cobalt-60, Iodine-131, 
Cesium-137/Barium-137m and Iridium-192 respectively. Approximately 1,152 urine samples 
could be analyzed in an eight-hour shift using a single gamma camera.  CONCLUSIONS: The 
use of the gamma camera for urine radiobioassay allows for high throughput volumes of 
samples and has sufficient detection sensitivity to meet dose-based decision guidelines. 
KEY WORDS: Internal dosimetry, Intake of radionuclides, Cobalt-60, Iridium-192, Iodine-131, 
Cesium-137, Radiological accidents, Radiological terrorism, Gamma Camera 
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I.  Introduction 
 
There have been several large-scale releases of radioactive material in the last forty years 
that have led to members of the public ingesting or inhaling radioactive materials. (Coeytaux, 
et al., 2015) This intake of radioactive materials can cause significant radiation 
contaminations which, concurrently, can increase the incidence of cancer in the 
contaminated populations. (ICRP, 2007) Unlike external exposures, which can be quickly 
stopped by moving out of the radiation field or cleaning contaminated surfaces, radioactive 
materials taken into the body only are removed through radioactive decay and biological 
elimination; yet the rate of biological elimination can be increased through timely medical 
intervention. Identifying which individuals have received an intake of radioactive material and 
which must receive medical intervention must occur soon after the contamination to limit 
the resulting radiation dose to that person.  Yet, while techniques exist to monitor potential 
intakes by an individual, we presently lack the analytical capacity to quickly and accurately 
assess radioactive material intakes in a large group of people. 
Internal Kinetics of Radioactive Materials 
Radioactive materials from radiological events may be inhaled, ingested, absorbed, or 
injected into humans.  The disposition of the radioactive material in a human body is a 
function of the chemical form and composition, size, and route of entry. (Bevelacqua, 2005) 
Once radioactive material is taken internally within a human body, the material will be 
removed from the body through radiological decay and biological elimination pathways such 
as through excretion in sweat, urine or feces. (ICRP, 2015) 
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As an example, iodine-131 is a common nuclear fission product that was released during the 
Chernobyl and Fukashima Daiichi nuclear accidents. (UNSCEAR, 2013) It also is widely used as 
a therapeutic agent for the treatment of thyroid diseases such as thyroid cancer and 
hyperthyroidism.  Elemental Iodine is highly volatile and, when released into the 
environment, becomes adsorbed onto dust particulates in the air where it can be inhaled or 
ingested.  Once inhaled, iodine is absorbed into blood as inorganic iodide.  Iodine in the blood 
is either absorbed by the thyroid or cleared through the renal system as presented in the 
biokinetic model of Figure 1. Once absorbed by the thyroid, the Iodine is stored and, when 
needed, converted into a hormone, either thyroxine or triiodothyronine, which are secreted 
through the body to regulate metabolic processes critical for growth and development. (ICRP, 
2017)  More than 90% an intake of elemental iodine is eventually released by renal clearance 
(urine) 48 -72 hours post intake.  Little of this intake is removed by fecal clearance or through 
sweat. 
 
 
 
 
 
 
Figure 1:  Simplified biokinetic model for iodine (ICRP 137, 2017) 
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Because of this, urine samples obtained after an accident can be used to estimate the amount 
of radio-iodine that was initially inhaled or ingested.  Such samples typically must be collected 
within one week post intake since samples collected beyond this time contain mostly recycled 
inorganic-iodine, which is a small amount as compared to the amount excreted via urine in 
the first few days.  Determining intakes from urine sample measurements collected beyond 
one week therefore is more difficult due to the lower concentrations of iodine-131 present 
in the urine sample. 
Historic Releases of Radioactive Material into the Environment 
Radioactive materials can be introduced into our environment either accidentally, such as the 
release of radioactive materials from the earthquake and tsunami-ravaged Fukushima Daiichi 
nuclear power plants in Japan, or intentionally, such as the assassination of Vladimir 
Litvinenko in England from polonium-210 poisoning in a public restaurant (Bailey, 
Etherington, Fraser, & Wilkins, 2010)  and the release of cesium-137 in the Goiania incident. 
(Coeytaux, et al., 2015) Such incidents caused large numbers of the surrounding population 
to become concerned that they were “contaminated” by radiation or radioactive material.  
While experience has shown that the actual number of contaminated individuals is small, the 
number of potentially contaminated individuals is large. (EPA, 2017) We will refer to 
individuals with an unknown internal contamination status as being “potentially 
contaminated,” while individuals confirmed to have received an intake of radioactive 
materials through measurement as being “contaminated.” Individuals confirmed through 
measurement as not having received an intake are referred to as “non-contaminated.” 
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In past events, we have learned that efforts to identify and separate the affected from the 
non- affected population is time-consuming and difficult (EPA, 2017) with the limiting factors 
being the lack of analytical equipment to perform the measurements, lack of trained 
personnel in using and interpreting the results from the measurements, and the inability to 
relocate the needed analytical equipment in a timely manner. (IAEA, 1988) (Ansari & Caspary, 
2015) It would be advantageous, therefore, to develop a precise and accurate technique for 
assessing potential radiation intakes and contaminations to ensure that resources, 
appropriate medical care and timely countermeasures can be focused where needed. 
Currently, potentially contaminated individuals are tested for radiological intakes using 
specialized equipment such as a whole-body counter, hand-held radiation detecting 
equipment, or collection of excreta sent off-site for analysis.  This is a major limitation of 
current practices of testing large numbers of potentially contaminated people; for example, 
it took four months to initiate the first measurements to identify intakes of radioactive 
material to the population surrounding the Daiichi Nuclear Power Plant. (Nomura, et al., 
2015) The reason for the delay was that the measurements required a special instrument 
(whole body counter) to be brought to a nearby site, and that each person had to be 
measured individually.  In addition, the elevated background radiation levels limited the 
devices accuracy (sensitivity) which resulted in the decision to move the device to a new 
location.  Ultimately, this 4-month delay prevented our ability to accurately and precisely 
detect iodine-131 intakes because of iodine’s three month biological and radiological removal 
rate from the body.  (Nomura, et al., 2015) 
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Current radiobioassay methods 
Radioactive material in the body can be measured through a variety of methods. (Bevelacqua, 
2005) For example, one can directly measure radioactive material in vivo by using instruments 
that detect photon radiations emitted from the radioactive material.  Alternatively, one could 
indirectly measure an intake of radioactive material, in vitro, by collecting and analyzing 
biological samples taken from the body, such as hair, tissue, blood, urine or feces. The 
quantity of the radioisotope in these samples are directly related to the amount of radioactive 
material that entered the body. 
The type of radiobioassay that should be performed on a person potentially contaminated by 
radioactive material depends on specific factors including: 
 The time of intake, 
 The mode of intake (e.g., inhalation, ingestion, wound, etc.), 
 If the intake is from a single radionuclide or multiple radionuclides, 
 The chemical and physical form, such as the particle size or solubility, of the 
radionuclide, 
 The rate of decay of the radionuclide, and 
 The metabolic characteristics and behavior of the radionuclide in the body. 
Currently, the most common method to radiobioassay a person potentially contaminated by 
radioactive material involves the in vivo monitoring of that person; this individual therefore 
must be present during the monitoring period, and only one person can be monitored at a 
time for each radiation detector.  Only photon-emitting radioactive material can be measured 
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using this method because the other forms of radiation, i.e., beta or alpha radiation, is not 
capable of penetrating the human tissue and be detected be a radiation measuring 
instrument.  Persons analyzed using this method are placed in a chair and one or more gamma 
sensitive radiation detectors are placed in close proximity to an area of the body, such as the 
upper torso, to measure the presence of radioactive material in the lungs.  Another common 
in vivo radiobioassay is the use of a NaI detector to measure the presence of the gamma-
emitting radionuclide iodine-131 in the thyroid of a person.  A small NaI crystal, such as a 2- 
inch x 2-inch crystal is placed close to a person’s thyroid gland and detects the gamma 
emissions from the presence of any iodine-131.  The typical amount of time to perform a 
measurement varies as a function of the energy of the gamma ray, and the frequency of how 
often the gamma ray is emitted by the radioactive material which will be used to adjust 
counting times to reach the desired level of sensitivity.  
 One study reported on the application of the gamma camera to in vivo radiobioassay in 
individuals.  (Anigstein, Olsher, & Loomis, 2010) A gamma camera has two large area radiation 
detectors (a.k.a. gamma camera heads). A more detailed discussion on the design of the 
gamma camera is discussed in a later section. The person is placed between the two gamma 
camera heads and used to detect the presence of gamma-emitting radionuclides. There are 
several limitations with this method.  Detector efficiency determinations required 
sophisticated modeling techniques.  A significant limitation is the detection efficiency is 
predicated on knowing the geometry of various body habitus of individuals and having them 
properly positioned between the two gamma camera heads so appropriate correction factors 
can be applied to the results. In addition, interpretation of the results is complicated and 
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requires specialized knowledge; estimating the quantity of radioactive material in a specific 
organ is needed to estimate intake and the gamma camera would require several (tens of 
minutes) to achieve the desired level of sensitivity.  This method greatly limits the number of 
people that can be assessed because of measurement preparation, and a lack of professionals 
who can interpret the data. 
In vitro bioassay monitoring is performed through urine and fecal testing.  Here, a potentially 
contaminated person submits a sample which is analyzed with a radiation detector to 
quantify the presence of radioactivity in terms of the source activity (rate of radiological 
decay) and to identify the radioactive isotope. Once quantified, this information can be used 
to estimate the total intake of radioactive material and the resulting radiation contamination 
the person will receive from that intake. These estimations, both, in vivo and in vitro 
monitoring, are evaluated according to various biokinetic models which predict the average 
biological transport of the isotope through the body. (ICRP, 2015) 
In vitro radiobioassay has the significant advantage that samples can be collected remotely 
and delivered to a hospital nuclear medicine department for analysis.  Additionally, analysis 
methods are simpler to implement, the results are simpler to interpret, and a large number 
of samples can be analyzed concurrently.  In vitro radiobioassay does require staff trained in 
use of the gamma camera, a CLIA certified laboratory, and appropriate equipment.   
Proposed method of radiation detection and analysis 
The goal of this dissertation is to present a method for the use a nuclear medicine gamma 
camera to conduct high volume throughput quantitative analyses to accurately and precisely 
evaluate radionuclide intakes.  
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Gamma cameras are used to detect gamma rays and x-rays, hence, radioactive materials that 
primarily emit alpha or beta radiation were eliminated from further evaluation.   This 
limitation did not have a large impact on the utility of our technique because almost all 
radioactive isotopes emit gamma rays and x-rays.  Although, some radioactive isotopes emit 
gamma rays so infrequently that use of the developed technique is not practical.  These 
radioactive isotopes were similarly excluded. 
A standard nuclear medicine gamma camera (General Electric Hawkeye V3) was used to 
measure the detection efficiency for technetium-99m (Tc-99m), which is a frequently used 
radionuclide in the nuclear medicine department.  The gamma camera was then modeled 
using MCNP v6.0 (LANL, 2017) to calculate detector efficiency for Tc-99m to compare the 
measured versus modeled results.  Verification and acceptance of the gamma camera model 
allowed the calculation of detector efficiencies for radionuclides not available for empirical 
analysis.   Detector efficiencies for the radionuclides of interest were used to develop the 
lower limit of detection and minimum committed effective dose for comparison to accepted 
regulatory guidelines. 
The bioassay method in this dissertation employs the use of a standard gamma camera to 
concurrently analyze a group of urine specimens.  A gamma camera is a device used in nuclear 
medicine departments in hospitals for the diagnosis of diseases and medical conditions.  
Radioactive materials chemically attached to pharmaceuticals are intentionally administered 
to the patient for the purpose of monitoring its physiological disposition via images produced 
by the gamma camera. The gamma camera employs a large area radiation detector sensitive 
to x- and gamma rays that, once detected, create images visible on a computer display.  The 
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use of a gamma camera to analyze bioassay samples is demonstrated with emphasis on the 
accuracy, sensitivity, and capacity to meet the time-critical needs for clinical decision-making 
post a radiological event. 
Monte Carlo Modeling 
Monte Carlo N-Particle (MCNP6.2) transport code (LANL, 2017) was developed by Los Alamos 
National Laboratory in 1957.  It has been continually updated and improved to the present.  
It is used primarily to simulate nuclear processes and is applied to a wide variety of areas 
where radiation interactions must be calculated.  The software allows the generation of 
three-dimensional models with radiation-related characteristics assigned to all molecules in 
the design.  A calculation involves the tracking of a single radiation particle, e.g., photons, 
electrons, neutrons, from the initial point of interaction with a molecule in the model to the 
end of its path, or when it exits the area of interest.  Each interaction results in the deposition 
of energy in the media per unit mass of that material (i.e., absorbed dose).  The software 
tracks the complete history of all interactions, and hence dose deposited, for each radiation 
particle included in the simulation.  For this dissertation, MCNP v6.0 was used to model a 
generic NaI detector, a urine specimen container, and urine media in the geometry expected 
to occur for a gamma counter.  Photon histories were used to quantify radiation detection 
events in the NaI crystal as a function of the number of photons emitted by the radionuclide 
of interest (i.e., detection efficiency). 
Review of past incidents 
Literature detailing actual radionuclide releases were evaluated to identify the radionuclides 
of concern for public dose. The list of radionuclides was reviewed for the type of radioactive 
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emissions and their detectability using a standard gamma camera. Table 1 summarizes the 
large-scale radiological incidents that have occurred over the past 40 years; this table includes 
the year the event occurred, the radionuclides released to the environment, the number of 
people potentially affected, the number of people verified as affected, and the time to 
perform initial intake measurements on members of the public. 
Table 1: Historical Radiological Events 
Event Year Type Radionucl
ides 
released 
# 
Potentially 
affected 
# 
affected 
Time to 
Initial 
Bioassay 
Three Mile 
Island (Battist 
& Peterson Jr., 
1979) 
1979 Nuclear 
Power 
accident 
85Kr, 131I, 
133Xe 
2,000,000 2 million 
(est.)  
None 
perform
ed 
Chernobyl  
(UNSCEAR 
2008 Report: 
Vol. II) 
1986 Nuclear 
Power 
accident 
85Kr, 131I, 
90Sr, 60Co, 
137Cs, 
133Xe 
Residents of 
northern 
hemisphere 
500 
million 
(est.) 
1988 
Goiania Brazil 
(IAEA,  1988) 
1987 Irradiator 
accident 
137Cs 112,000 249 Four 
months 
Litvinenko 
(Harrison, et 
al., 2017)  
2006 Intentional 
poisoning 
210Po 990 137 1 month 
Fukushima 
Daiichi (Samet 
& Chanson, 
2015) 
2011 Nuclear 
Power 
accident 
85Kr, 131I, 
90Sr, 60Co, 
137Cs, 
133Xe 
Residents of 
northern 
hemisphere 
32 million 
(est.) 
 
4 months 
 
Three Mile Island  (Ahearn, 1979) (Battist & Peterson Jr., 1979) The Three Mile Island Unit 2 
reactor, near Middletown, Pa., partially melted down on March 28, 1979. Investigations 
revealed a combination of equipment malfunctions, design-related problems, and worker 
errors led to TMI-2's partial meltdown and very small off-site releases of radioactivity. This 
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was the most serious accident in U.S. commercial nuclear power plant operating history, 
although its small radioactive releases had no detectable health effects on plant workers or 
the public.   
The primary releases from TMI included krypton-88, xenon-133, xenon-133m, xenon-135, 
xenon-135m and iodine-131. The number of people potentially impacted by TMI was 
estimated as 2 million people. The majority (>99%) of the radioactivity released to the 
environment during the event were noble gases which are inhaled and immediately exhaled 
from the body resulting in no measurable radiation intake. No internal assessments of 
radiological intakes were conducted for members of the public following this incident. 
Chernobyl - On April 26, 1986, human error and plant design flaws led to the steam explosion 
and complete meltdown of the graphite-moderated nuclear reactor.  Within a few weeks of 
the accident, 30 workers had entered the area without proper respiratory protection died 
from radiation contamination and radiation injuries occurred to several hundred other 
workers.  Large areas of Russia, Belarus, and Ukraine were radioactively contaminated. 
Contamination of the population was primarily caused by releases of iodine-131 (internal 
contamination), cesium-134 and-137 (internal contamination and external exposure).  
(UNSCEAR, 2008) Other radionuclides of biological significance released included plutonium-
239, 240 and 241, and americium-241 (due to ingrowth from the decay of plutonium-241). 
The number of people potentially impacted by the event was not provided, but radioactivity 
was reported as being measured in all countries in the northern hemisphere.  (UNSCEAR, 
2008)  Impacted individuals were reported as 98 million for Belarus, Ukraine and Russia 
collectively, and 500 million for inhabitants of distant countries.  Assessment of intakes in the 
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general public was initially performed within one week for 30 individuals in the Czech 
Republic, but wide-scale measurements for the population were not performed until two 
years post event. Table 2 presents the number of individuals, average thyroid dose and 
average effective dose from the Chernobyl accident. 
Table 2:  Number of individuals impacted by the Chernobyl Accident 
Population group 
Size 
(thousands) 
Average 
thyroid dose 
in 1986 (mGy) 
Average 
effective dose 
in 1986 –2005 
(mSv) 
Recovery operation workers 530 Not available 117 
Evacuees 115 490 31 
Inhabitants of contaminated areas 
of Belarus, Russia and Ukraine 
6,400 102 9 
Inhabitants of Belarus, Russian 
Federation and Ukraine 
98,000 16 1.3 
Inhabitants of distant countries 500,000 1.3 0.3 
* Adapted from UNSCEAR 2008 Report Volume II 
Goiania (IAEA, 1988) – On September 13, 1987, a sealed source containing cesium-137 was 
removed from an abandoned teletherapy device and subsequently intentionally ruptured 
releasing its contents into the environment.  The nature of the source contents was unknown 
to those who ruptured the source.  The radiological nature of the accident was not discovered 
until September 29, 1987.  In the ensuing two weeks, news of the accident spread to the 
population and more than 129,000 people converged on the local Olympic Stadium to be 
screened.  A total of 249 people were identified to be contaminated with cesium-137.  Of this 
group, 129 people also had ingested and/or inhaled radio-cesium.  The lack of trained 
personnel and instrumentation were identified as significant barriers to an effective 
response. 
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Litvinenko (Harrison, et al., 2017) – On 1 November 2006, a former Russian spy, Alexander 
Litvinenko, became ill after meetings with a former colleague at a sushi bar and hotel in 
London England.  Three days later he was admitted to a local hospital and subsequently 
suffered a heart attack and died in the hospital on 22 November 2006.  The radioisotope 
(polonium-210) was not identified until 24 November 2006.  A total of 990 people were 
potentially contaminated by the polonium-210.  Of this group, 779 people were offered to 
have their urine analyzed and 738 agreed.  Of the 738 urine samples collected and analyzed, 
137 had positive results. The quantity of polonium-210 detected in the 137 persons was low 
and not life threatening. 
Fukushima - (Samet & Chanson, 2015) On 11 March 2011, the Fukushima Daiichi Nuclear 
Power Plant incident, resulted in an acute intake of iodine-131 and cesium-137 in the initial 
stage of the incident and was the primary source of internal radiation contamination 
(Tsubokura et al. 2013). From March 26-30, 2011 limited in-vivo sampling was performed of 
1,080 individuals for iodine-131.  By July 2011 internal contamination screening was 
performed using a chair-type Whole Body Counter (WBC) (Anzai Medical Co. 2014). Between 
11 July 2011 and 29 July 2011 a sodium iodide (NaI) detector (5-inch diameter 3-inch 
thickness) was mounted on the back of a chair, and from that location, was able to count 
gamma isotopes (Hayano et al. 2014). However, the chair-type WBC provided insufficient 
shielding against background gamma rays. It was replaced by a better-shielded standing-type 
WBC (FASTSCAN Model 2251, Canberra Inc., USA) on 26 September 2011.  
Basis for radionuclides considered in this dissertation 
Radioactive materials could be released into the environment from events such as a fire at a  
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nuclear power plant, nuclear fuel manufacturing facility, radioactive source manufacturing 
facility, or a radioactive material use laboratory.  Intentional incidents include intentional 
damage to nuclear facilities described above, radiological dispersal devices involving small 
and highly localized sources, the dispersal of large amounts of radioactive materials over large 
areas, and finally nuclear weapons, whether resulting in a nuclear yield or not.  
The geographic extent of radiological hazards following an incident will depend on the 
radioactive material involved, and the mechanism by which it was released to the 
environment, e.g., fire, explosion, etc., and the environmental conditions at the time of the 
incident.  Once taken into the human body, the disposition and elimination of the radioactive 
material will depend on its physical and chemical properties. 
During and immediately after a radiological incident there are many decisions that must be 
made in a short period of time by a range of governmental organizations. (EPA, 2017) (Ansari 
& Caspary, 2015) Decisions must be made by appropriate organizations in the interests of law 
enforcement, public health and safety, damage to infrastructure, psychosocial impacts, and 
environmental concerns. 
Many of the decisions are based upon the availability of data, and the results of models used 
to estimate potential impacts.  Human radiation contamination data immediately following 
an incident is difficult to obtain due to logistic demands for responding to the event, and the 
lack of radiological instrumentation sufficient to handle the capacity needs, and trained 
individuals to perform the measurements.  Employing countermeasures to reduce 
radiological uptake to humans is possible only if accurate information can be received in a 
timely manner. (Nomura, et al., 2015) 
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Based on these events and consideration of possible future terrorist-related events, Table 3 
presents the radionuclides selected for evaluation as isotopes of concern for this proposed 
technique: 
Table 3: Radionuclides of Interest 
Radionuclide Half-life Emission type 
131I 8.1 days β, ϒ 
137Cs/137mBa 30.1 years β, ϒ 
60Co 5.27 years β, ϒ 
192Ir 73.8 days β, ϒ 
 
Radioactive isotopes, such as polonium-210, with negligible gamma yields (i.e., infrequent 
emissions) were excluded from the radionuclides of interest.   
Current Guidance 
The Centers for Disease Control (CDC), Radiation Studies Branch, addressed population 
monitoring after a radiological incident in a 2014 report (CDC, 2014) The CDC defines 
population monitoring as “a process that begins after a radiation incident is reported and 
continues until all potentially affected people have been monitored and evaluated for: 
 Needed medical treatment 
 The presence of radioactive contamination on the body or clothing 
 The intake of radioactive materials into the body 
 The removal of external or internal contamination 
 The radiation dose received and the resulting health risk from the contamination long-
term health effects” 
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The CDC guide is intended to advise emergency response personnel on the processes needed 
for monitoring potential intakes in a population contaminated by radioactive materials.  
Bioassay samples are identified as a powerful diagnostic tool for assessing internal 
contamination, and in the event of radiological dispersal, the urine sample is the most useful 
for dose estimation.  Laboratory analysis capabilities are identified as a critical part of 
planning and should address: 
 Analytical capability 
 Sample prioritization and triage 
 Turnaround time 
 Sample throughput 
 Sample volume 
 Sample storage capacity 
 Confidentiality assurance 
 Protocols for reporting analytical result” 
Analytical laboratories must also be capable of complying with Clinical Laboratory and 
Improvement Amendments (CLIA).  CLIA certifies that a laboratory has the necessary 
equipment, personnel and procedures to accept human specimens for the purpose of 
performing specific laboratory procedures.  
The National Council on Radiation Protection and Measurements published Management of 
Persons Accidentally Contaminated with Radionuclides: Handbook, Report No. 161. (NCRP, 
2013) The guidelines are expressed as a dose (excluding isotopes of iodine) as: 
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 0.25 Sv (50-year effective dose) whole body 
 0.25 Gy-Eq (30 day RBE-weighted absorbed dose) to the bone marrow 
 1 Gy-Eq (30-day RBE-weighted absorbed dose) to the lung 
Iodine is excluded because it concentrates in the thyroid gland and the highest contamination 
for an intake is to the thyroid rather than the whole body. 
The values are for adults. For children and pregnant women, the screening value is reduced 
to 20% of the CDG.  The screening value for isotopes of iodine is age dependent.  The limiting 
dose for which countermeasures are recommended is 0.05 Gy (i.e., for children up to 18 and 
pregnant or lactating women).  These values are consistent with guidance issued by the 
International Commission on Radiological Protection. Figure 2 shows the logic diagram for 
converting the Clinical Decision Guideline (CDG) to a quantity of a radionuclide that would be 
measured in urine at a time “t” post-incident. 
 
 
Figure 2:  Logic diagram for converting Clinical Decision Guidelines to measurements of 
radionuclides in urine specimens 
Concept of Minimum Detectable Dose 
For this technique to be useful, it must have the precision to measure the radiation 
contamination detailed in NCRP 161. To that end, the minimum detectable dose (MDD) is a 
statistical characterization of the device’s radiation detection limits based on accepted a 
priori assigned confidence levels. (Currie, 1968)  Because radiation is also present in our 
natural environment, background radiation will act as a confounding factor in any 
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measurement.  Therefore, we must apply a statistical test to separate a true positive sample 
from one that is indistinguishable from background radiation.  The test involves establishing 
a null hypothesis (H0) and an alternative hypothesis (H1).  The null hypothesis is the general 
statement that no activity is present in the sample while the alternative hypothesis is the 
statement that activity is present in the sample.  (Currie, 1968) 
We will use a sample containing no radioactivity to serve as our control sample (blank). Our 
blank sample then is measured by the gamma camera’s NaI detector to quantify the 
background radiation contribution to a sample. However, to determine our MDD we are only 
interested in accounting for those gamma rays that are of the same energy as for the 
radiation we are looking to detect.  We accomplish this by placing a “window” around the 
energy peak of interest and we can count the number of detections from background 
radiation.  The distribution of counts in this region can be characterized by a population mean 
(μB) and standard deviation (σB).  If we place a sample on the detector and count the number 
of detections within that energy window we can express the mean count (CB) and the 
standard deviation (sB).  The net count is obtained by subtracting the background counts from 
the sample counts.  This will result in a zero-mean count frequency distribution that is 
approximately normally distributed (bell-shaped).  The standard deviation of the distribution 
is obtained by propagating the individual standard deviations of the terms. 
𝜎0 =  √𝜎𝐵
2 +  𝑠𝐵
2 (Eq. 1) 
This distribution is used to determine a critical level to decide when activity is present.  The 
critical level, Lc, is the net count in a zero-mean count distribution that has a probability of 
being exceeded.  The general practice is to set the probability (α) at 5% meaning that we 
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expect one out of every twenty blank samples analyzed on our system to produce a signal 
that exceeds our critical level, Lc, by random chance alone.  To summarize, if a sample count 
is less than the critical level, we accept the null hypothesis and conclude that no activity is 
present in the sample.  Alternatively, if the count is above the critical level, Lc, then the null 
hypothesis is rejected and we conclude activity is present in the sample. In the case of our 
blank sample, we expect that twenty measurements of this sample will have one 
measurement that will exceed Lc for an  = 5%. Therefore, we also expect that if we measure 
twenty blank samples, one of those samples will exceed Lc which would cause us to 
incorrectly conclude that activity is present in the sample when in fact there is none (i.e. a 
false positive).  In this case, the critical level is calculated as: 
Lc = kα σB   (Eq. 2) 
Where kα is the value of the standard normal deviation for a normal distribution using a one-
tailed level of 1 – α.  The corresponding value of kα is 1.645 for an  = 5%.  Therefore, coupling 
Eq 1 and Eq. 2, the critical level for a sample containing no activity measured in the presence 
of background radiation ( that is, the standard deviation of the sample and background would 
be equal  so that σB = sB ) becomes: 
𝐿𝑐 = 1.645 √2𝑠𝐵
2 = 2.33 𝑠𝐵
2  (Eq. 3) 
Based on our critical limit, we next can derive a detection limit, LD, which is the number of 
counts that the detector can “detect” with a confidence level . The detection limit typically 
is larger than Lc based on our decision criteria, , to allow our detector to obtain a false 
negative (that is, radiation is present on our sample but creates a measurement that is lower 
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than Ld. Ld is typically chosen to produce a false negative at 5% confidence and will almost 
always will correctly determine that activity is present. However, similar to Lc, the counts are 
distributed normally and it is common to select a probability of 5% meaning that we will 
accept the probability of stating that no activity is present when it is present.  The equation 
for LD is: 
𝐿𝐷 = 𝐿𝐶  + 𝑘β  σD  (Eq. 4) 
Where kβ is the value of the standard normal deviate for the normal distribution using a one-
tailed probability.  Replacing like variables we see LD is: 
𝐿𝐷 = 𝐶𝑆  + (𝐶𝐵 −   μB)   (Eq. 5) 
The standard deviation is obtained by propagating the errors in the gross count.  
𝜎𝐷 = √(𝐶𝑆 +  𝜎0
2)  =  √𝐿𝐷 +  𝜎0
2  (Eq. 6) 
Solving for LD yields: 
LD = 2.71 + 4.65 sB   (Eq. 7) 
This LD describes the net count having a 95% probability of being detected when a sample 
contains activity at LD, and a 5% probability of incorrectly concluding that activity is present 
when it is not. (Currie, 1968)  
The area of the detector that is used to measure the sample and background is limited to a 
smaller area of the detector called the Region of Interest (ROI).  Converting this value of LD to 
the dose that corresponds to this detection level takes into account a correction for the 
number of gamma rays emitted by the radionuclide at energy E (Y) and the efficiency of the 
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detector to count gamma rays of the energy E.  Urine samples are expressed in units of 
activity per unit volume of the urine being measured.  This value is then normalized to the 
reference man daily excretion of urine (1400 ml/day). (ICRP, 2015) These factors result in the 
Minimum Detectable Intake (MDI):   
𝑀𝐷𝐼 (𝐵𝑞) = (
2.71+4.65√𝐵𝑅𝑂𝐼
𝑌𝑛(
ϒ
𝑑
)𝐸𝑛(
𝑐
ϒ
)(
𝑉𝑠(𝑚𝑙)
1400𝑚𝑙
)
)  (Eq. 8) 
Where BROI is the background counts in the region of interest, Yn is the photon yield of energy 
Ei, and En is the efficiency of the detector for the nth radionuclide of interest, and Vs is the 
volume of urine in the specimen container normalized to reference man daily urinary 
excretion.  The minimum detectable dose (MDD) is then calculated by multiplying the MDI by 
the urinary excretion fraction expressed as dose per unit intake for a specific radionuclide or: 
𝑀𝐷𝐷 (𝑆𝑣) =  𝑀𝐷𝐼(𝐵𝑞) × 𝑈𝐸𝐹 (
𝑆𝑣
𝐵𝑞
)   (Eq. 9) 
II.   Materials and Methods 
We are investigating using a gamma-camera to detect radioactive materials in the urine 
bioassay of a potentially contaminated person. The intake, and therefore the expected 
radiation absorbed dose delivered to the person, can be estimated using a Biokinetic Model 
that simulates the transport of the radioisotope through the body and ultimately deposited 
into urine. 
Biokinetic Model for Urinary Excretion  
The biokinetic model to estimate the number of radiological decays that occur in the human 
body and transfer of the radioactive elements from one organ or “compartment” to another 
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is mathematically derived using general kinematics which assumes that the rate of transport 
from one compartment to the next and that the rate of radiological decay remains constant. 
This results in a series of first order differential equations that can be solved to determine the 
number of radioactive atoms in a specific compartment at a time “t” post intake.  For 
example, a simplified three compartment model is described in Figure 3: 
 
  
Figure 3: Simplified compartment model 
 
where, Ni is the removal of radionuclide in the ith compartment to the next, and lambda (𝜆) is 
the removal rate for that compartment.  The removal rate is a combination of the decay 
constant and biological removal constant from the compartment (i). 
The removal rate is constant for each compartment and can be shown as thus,  
Compartment 1:  
𝑑𝑁1(𝑡)
𝑑𝑡
=  − 𝜆 1N1 (t)    (Eq. 10) 
Compartment 2:  
𝑑𝑁2(𝑡)
𝑑𝑡
=  + 𝜆 1N1 (t)   ̶   𝜆 2N2 (t)   (Eq. 12) 
Compartment 3:  
𝑑𝑁3(𝑡)
𝑑𝑡
=  + 𝜆 2N2 (t)   ̶   𝜆 3N3 (t)   (Eq. 13) 
Rearranging the terms:  
𝑑𝑁1(𝑡)
𝑑𝑡
 + 𝜆 1N1(t) = 0 (i)      (Eq. 14) 
𝑑𝑁2(𝑡)
𝑑𝑡
   +   2N2(t) = 𝜆 1N1(t)  (ii)       (Eq. 15) 
N1 N2
 
 N1 
N3 
1 2 3 
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𝑑𝑁3(𝑡)
𝑑𝑡
   +   3N3(t)  = 𝜆 2N2(t) (iii)      (Eq. 16) 
Using Laplace transforms to solve the three equations yields: 
N1 (t) = N1 (0) e-𝜆1t       (Eq. 17) 
N2 (t) = N1 (0) 𝜆1 [
𝑒−𝜆1𝑡
(𝜆2−𝜆1)
+
𝑒−𝜆2𝑡
(𝜆1−𝜆2)
]     (Eq. 18) 
N3 (t) = N1 (0) 𝜆1 𝜆2 [
𝑒−𝜆1𝑡
(𝜆3−𝜆1)(𝜆2−𝜆1)
+
𝑒−𝜆2𝑡
(𝜆3−𝜆2)(𝜆1−𝜆2)
+
𝑒−𝜆3𝑡
(𝜆1−𝜆3)(𝜆2−𝜆3)
] (Eq. 19) 
The human body is more complicated in that it is generally represented with nine interrelated 
compartments as shown in Figure 4 below. The compartments that are impacted depend on 
the radionuclide chemical and physical form.  For this dissertation, the biokinetic models used 
were those presented in ICRP 134 and 137. (ICRP, 2016) (ICRP, 2017) 
Biokinetics of each radionuclide of interest in the human body is described by two sets of 
differential equations.  The first set describes the number of atoms in the compartments 
during the intake of a radionuclide during an incident.  The second set describes the processes 
after the termination of the intake. 
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Figure 4: General diagram for Biokinetics of radionuclides 
(Adapted from (ICRP, 2017)) 
The total number of atoms during an intake U is assumed to be constant for the individual 
and is given as: 
𝑈 =
𝐴0
𝜆𝑠
     (Eq. 20) 
Where A0 is the intake of activity, and 𝜆s is the decay constant for the radionuclide.  The ratio  
𝑅 =
𝑈
𝑇
     (Eq. 21) 
Where T is the duration of intake and yields the number of intake atoms per unit time.  The 
duration of intake is dependent on the nature of the incident, the time to discovery of a 
release, and the time to remove the individual from the radiological environment.  In this 
dissertation, it is assumed that the individual is removed from the radiological environment 
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and that intake via inhalation, ingestion, wounds and dermal absorption, and removal via 
exhalation and extrinsic mechanisms has been terminated (R=0). 
Therefore, the differential equations describing the time rate of change in the number of 
atoms in each of the nine compartments post incident are as follows:  
𝑑𝑁1
𝑑𝑡
=  − 𝜆 𝑁1  −  𝜆1,2𝑁1  +  𝜆2,1𝑁2      (Eq. 22) 
 𝑑𝑁2
𝑑𝑡
=  − 𝜆𝑁2  −  𝜆2,1𝑁2  −  𝜆2,4𝑁2  −  𝜆2,5𝑁2  −  𝜆2,6𝑁2  −  𝜆2,7𝑁2  +  𝜆1,2𝑁1  + 𝜆3,2𝑁3  +
 𝜆4,2𝑁4  +  𝜆5,2𝑁5  +  𝜆6,2𝑁6  +  𝜆7,2𝑁7      (Eq. 23) 
𝑑𝑁3
𝑑𝑡
=  − 𝜆 𝑁3  −  𝜆3,2𝑁3  +  𝜆1,3𝑁1      (Eq. 24) 
𝑑𝑁4
𝑑𝑡
=  − 𝜆 𝑁4  −  𝜆4,5𝑁1  −  𝜆4,2𝑁4  + 𝜆2,4 𝑁2     (Eq. 25) 
𝑑𝑁5
𝑑𝑡
=  − 𝜆 𝑁5  −  𝜆5,2𝑁5  +  𝜆4,5𝑁4  +  𝜆2,5 𝑁2    (Eq. 26) 
𝑑𝑁6
𝑑𝑡
=  − 𝜆 𝑁6  −  𝜆6,2𝑁6  +  𝜆2,6 𝑁2      (Eq. 27) 
𝑑𝑁7
𝑑𝑡
=  − 𝜆 𝑁7  −  𝜆7,2𝑁7  −  𝜆7,8𝑁7  +  𝜆2,7 𝑁2     (Eq. 28) 
𝑑𝑁8
𝑑𝑡
=  − 𝜆 𝑁8  +  𝜆7,8 𝑁7        (Eq. 29) 
𝑑𝑁9,10,11
𝑑𝑡
= 0          (Eq. 30) 
Here, 𝜆 is the effective removal constant for the radionuclide (i.e., 𝜆R + 𝜆B), and Ni is the 
number of atoms in the Nth compartment.  And 𝜆1,2, 𝜆1,3, 𝜆2,1, 𝜆1,2, 𝜆2,4, 𝜆2,5, etc. are transfer 
rates from one compartment to another.   For example, 𝜆1,2 is the transfer rate from 
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compartment 1 to compartment 2.  The value is negative (-) with respect to N1 but positive 
with respect to N2.  
The differential equations presented above are solved and the solution rearranged to 
calculate the urinary excretion at time (t) post termination of the intake.  
The biokinetics for the systemic models for cobalt-60, iodine-131, cesium-137 and iridium-
192 are presented in Figures 5 through 8, respectively. (ICRP, 2016) (ICRP, 2017) 
 
Figure 5: Biokinetic Model for Cobalt-60 (ICRP 134, 2016) 
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Figure 6: Biokinetic Model for Iodine-131 (ICRP 137, 2017) 
 
Figure 7: Biokinetic Model for Cesium-137 (ICRP 137, 2017) 
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Figure 8: Biokinetic Model for Iridium-192 (ICRP 137, 2017) 
The input parameters used to calculate intake and excretion were empirically determined 
through human and animal studies as presented in ICRP 130, 134 and 137. The resulting daily 
urinary excretion fractions as a percent of intake are presented in Table 4. 
Table 4:  Daily Urinary Excretion Fractions for the Radionuclides of Interest 
Days 
Co-60 (Sv/Bq) 
Fraction in daily urine 
I-131 (Sv/Bq) 
Fraction in daily urine 
Type F Type M Type S Type F Type M Type S 
1 1.30E-07 9.30E-07 9.30E-05 3.20E-08 4.30E-08 2.00E-07 
2 3.10E-07 2.20E-06 2.20E-04 1.60E-07 1.30E-07 5.40E-07 
3 5.50E-07 3.80E-06 3.90E-04 1.20E-06 9.00E-07 3.80E-06 
4 8.10E-07 5.30E-06 5.50E-04 9.50E-06 4.80E-06 2.20E-05 
5 1.10E-06 6.90E-06 7.30E-04 4.00E-05 1.10E-05 5.50E-05 
6 1.40E-06 8.50E-06 9.20E-04 5.80E-05 1.40E-05 7.50E-05 
7 1.70E-06 1.00E-05 1.10E-03 5.70E-05 1.60E-05 8.70E-05 
8 2.10E-06 1.20E-05 1.30E-03 5.50E-05 1.80E-05 9.70E-05 
9 2.60E-06 1.40E-05 1.60E-03 5.40E-05 2.00E-05 1.10E-04 
10 3.00E-06 1.50E-05 1.80E-03 5.50E-05 2.20E-05 1.20E-04 
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15 5.50E-06 2.20E-05 2.80E-03 6.60E-05 3.40E-05 1.90E-04 
30 1.50E-05 3.60E-05 5.10E-03 2.00E-04 1.20E-04 6.70E-04 
45 3.00E-05 4.60E-05 6.60E-03 7.70E-04 4.80E-04 2.50E-03 
60 4.80E-05 5.30E-05 7.50E-03 3.00E-03 1.90E-03 9.70E-03 
90 7.90E-05 6.60E-05 8.50E-03 4.80E-02 3.00E-02 1.40E-01 
180 1.80E-04 1.20E-04 1.10E-02 N/A N/A N/A 
365 4.60E-04 3.50E-04 1.50E-02 N/A N/A N/A 
Days 
Cs-137 (Sv/Bq) 
Fraction in daily urine 
Ir-192 (Sv/Bq) 
Fraction in daily urine 
Type F Type M Type S Type F Type M Type S 
1 3.40E-07 1.20E-06 6.00E-05 6.00E-08 8.00E-07 2.30E-05 
2 7.20E-07 1.90E-06 9.40E-05 3.10E-07 3.40E-06 9.90E-05 
3 1.10E-06 3.10E-06 1.50E-04 4.90E-07 5.50E-06 1.70E-04 
4 1.50E-06 4.20E-06 2.10E-04 6.40E-07 7.00E-06 2.10E-04 
5 1.70E-06 5.00E-06 2.50E-04 7.90E-07 8.20E-06 2.60E-04 
6 1.90E-06 5.60E-06 2.80E-04 9.40E-07 9.40E-06 3.00E-04 
7 2.10E-06 6.10E-06 3.00E-04 1.10E-06 1.10E-05 3.40E-04 
8 2.30E-06 6.50E-06 3.20E-04 1.20E-06 1.10E-05 3.80E-04 
9 2.40E-06 6.80E-06 3.40E-04 1.40E-06 1.20E-05 4.10E-04 
10 2.40E-06 7.00E-06 3.50E-04 1.50E-06 1.30E-05 4.50E-04 
15 2.70E-06 7.70E-06 3.90E-04 2.20E-06 1.70E-05 6.00E-04 
30 3.10E-06 8.70E-06 4.40E-04 4.90E-06 2.70E-05 1.00E-03 
45 3.50E-06 9.70E-06 5.00E-04 8.00E-06 3.50E-05 1.40E-03 
60 4.00E-06 1.10E-05 5.50E-04 1.10E-05 4.40E-05 1.70E-03 
90 5.10E-06 1.30E-05 6.80E-04 1.90E-05 6.60E-05 2.40E-03 
180 1.10E-05 2.40E-05 1.20E-03 6.90E-05 2.10E-04 6.10E-03 
365 4.90E-05 8.70E-05 3.50E-03 7.50E-04 2.20E-03 4.10E-02 
 
The daily urinary excretion fraction for each radionuclide is derived from empirical data taken 
from actual intakes of the radionuclide by humans during an unintentional contamination, or 
by humans and animals for surrogates used in controlled laboratory settings. The pathways 
for the radionuclides assessed are via inhalation and ingestion based on the Human 
Respiratory Tract Model.  This model allows for three “Types” of absorption using 
experimental data, Type F (fast), Type M (Moderate) and Type S (Slow).  Type F assumes that 
the amount absorbed into blood by 30 days after an intake is greater than a similar material 
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with a constant rate of absorption into blood with a half-time of 10 days.  Type S is assumed 
if a similar element were absorbed into blood with a constant rate of absorption of 0.001 per 
day.  If insufficient data exists, the ICRP recommends using a Type M for most elements as a 
default. (ICRP, 2015)   
Absorbed dose and dose equivalent 
The presence of radioactive material in an organ results in its emitted radiations being 
absorbed by the tissue and cells of the organ.  Some radiation can also escape the organ and 
interact and be absorbed in adjacent organs.  Energy absorbed by cells cause damage to the 
cellular components including the DNA.  Such damage is usually repaired by cellular 
mechanisms, but can also lead to mutations that cause cancer.  The energy absorbed by the 
tissues is described as “absorbed dose” and is expressed in units of Joules per kilogram.   
Outcomes to persons receiving absorbed doses to an organ have been extensively studied.   
Quantitative risk of cancer development and other detrimental effects from absorbed doses 
have been published (ICRP, 2007) and are expressed in terms of a dose equivalent.  The dose 
equivalent is therefore a measure of the biological damage to living tissues from radiation 
contamination.  It is expressed in units of Sieverts.  (Koenig, et al., 2005) 
Gamma Camera Operation  
The gamma camera is used to image the distribution of a radioactive pharmaceutical in a 
patient for diagnostic purposes. A sodium-iodide or solid-state detector is used to detect the 
gamma or x-ray emissions from the radioactive component of the radiopharmaceutical in the 
patient, and the detected emissions are processed by a computer and software to produce a 
two or three-dimensional image.  A gamma camera may have one or two detectors that pass 
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over the patient while lying motionless on a table.  The detectors are mounted on a gantry 
and rotate in a circle around the patient to produce the three dimensional, i.e., tomographic, 
image. (GE, 2012) 
Typical sodium iodide crystals range from 6.4 to 12.7 mm in thickness for most commercially 
available systems.  The crystal thickness is intended to optimize detection efficiency and 
intrinsic spatial resolution.  The energies the gamma camera is used to detect in nuclear 
medicine applications range from 100 to 200 keV. Thicker crystals are used to improve the 
detection efficiency for higher energy gamma emitter such as the 511keV photons produced 
from Fluorine-18 used in positron emitting tomography. The 2π detection efficiency for 
photon energies from 100 to 200 keV for various thicknesses is presented in Figure 9 below. 
 
Figure 9: Reported NaI Detector Efficiencies for various photon energies and detector 
thicknesses (Adapted from Anger HO: Radioisotope cameras. (Hine, 1967) 
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Modern crystals are typically rectangular in shape with sizes up to 40 cm x 60 cm.  Older style 
gamma cameras employed round crystals 25 to 50 cm in diameter.  Below the crystal is an 
array of photomultiplier tubes coupled to the crystal by a layer of silicone-based adhesive.  
The tubes are arranged in a hexagonal fashion to optimize coverage of the detector area. The 
entire detector and PM tube assembly is light-tight and lead-lined to reduce background 
sources of signal.  Typical PM tubes are about 5 cm in diameter, and a single crystal may be 
monitored by 15 to 60 tubes.  There are various detector/PM tube designs that are intended 
to minimize signal distortion and loss.  A schematic cross-section of a gamma camera 
assembly is presented in Figure 10 below. 
 
 
Figure 10 – Cross sectional view of a typical gamma camera detector 
 
Current gamma cameras have an energy resolution of 9% to 10% and the detection efficiency 
is typically about 12% at 140 keV.  However, the detector efficiency is a function of the 
detector thickness and energy of the photon. 
The software used to analyze the signal and produce a two or three-dimensional image is 
unique to the manufacturer of the gamma camera.  In general, an image is displayed on a 
computer monitor.  For this study, two-dimensional images were produced, and the software 
used to draw a region of interest in the monitor's pixel array, and a summation of the 
detected photons within the region. 
NaI (Tl) crystal 
Photomultiplier Tubes 
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The gamma camera used for the measurements was a General Electric Hawkeye V3. (See 
Figure 11.)  The Hawkeye consists of two heads each possessing a 3/8-inch thick NaI crystal 
backed by 59 photomultiplier tubes.  The detectable energy range is reported by GE for this 
thickness crystal is 40 – 520 keV. (GE, 2012) There is a one-inch thick crystal model available 
as well with the detectable energy range extending to 900 keV.  The gamma camera is used 
to analyze a plastic container containing simulated urine (See Figure 12).  For the purposes of 
this dissertation, water was used as a surrogate for urine.  Water was selected because there 
are no significant differences in radiation attenuation properties between urine and water.  
Detector intrinsic spatial resolution and detector efficiency is a function of the following 
variables - gamma energy, photon flux at the detector surface, and the height and areal 
extent of the liquid volume in the cylindrical specimen container.  The experimental method 
to address each of the variables is discussed. 
 
Figure 11 – Image of the General Electric Hawkeye V3 Gamma Camera (Courtesy of 
Lahey Medical Center, Burlington MA) 
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Urine Specimen Collection and Analysis 
The advantage of this method is that hospitals commonly use gamma cameras and frequently 
use Urine specimen containers. Containers of urine specimens are placed on a gamma 
camera “head” housing the detector. Samples are counted for a specific time interval.  The 
detected “counts” of radioactivity are converted into decays and specific correction factors 
are applied.  Once the amount of radioactivity measured in the container is quantified, the 
amount of the original intake can be estimated through applying radionuclide and intake 
pathway biokinetic models.  The amount of the original intake is expressed as the radiation 
dose that will be delivered to that individual over the subsequent 50-year period (i.e., 
committed effective dose). 
 
Figure 12 – Image of a urine specimen container placed on a General Electric Hawkeye V3 
Gamma Camera detector 
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Gamma Camera settings/protocol 
As previously discussed, the gamma camera is equipped with two detector heads with the 
detection surface area parallel to one another.  One detector was oriented horizontally with 
the detector facing up so that the specimen container could be placed onto the detector as 
shown in Figure 12.  To detect low amounts of radioactivity, collimators were removed from 
a General Electric Hawkeye gamma camera to prevent the effect they produce on reducing 
detection efficiency.  For the detector to operate, a clear Lucite sheet with associated 
electronics must be inserted in place of a collimator so the electronics recognized that a 
collimator was not being used.     
Posterior imaging was used for counting using a 256 x 256 pixel matrix, 1.23 magnification 
and a 10% energy window centered on the 140 keV peak for Tc-99m.  The Exceleris software 
package provided by GE with the gamma camera was used to process and analyze the image 
data. 
Detector response to background radiation 
A three-minute background measurement was performed to determine the total 
contribution of background radiation to the signal.  A urine specimen container filled with 
water to the 100 ml mark was placed on the center of detector 2 and the three-minute count 
initiated to obtain the background count rate.  The background count rate was determined 
for a unit region-of-interest that could be reproduced in size and position on the display for 
subsequent counts.  Background counts accumulated during the counting period were 
provided by the software for each region-of-interest.   
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Effect of sample volume on detector response 
The urine specimen container can be modeled as a right cylindrical volume containing a 
homogeneous concentration of a radionuclide in a liquid medium.  The detector response is 
a function of the height of the liquid column, i.e., as the column increases in height, radiation 
emitted in the direction of the detector in the upper layers of the liquid column must pass 
through a greater thickness of the liquid thus, resulting in the attenuation of more photons 
as compared to layers closest to the detector.  In addition, as the column height increases, 
fewer photons are emitted in the direction of the region of interest on the detector.   
The contribution of photons reaching the detector as a function of height in the liquid 
medium column was determined by MCNP using the energy of the energy of the emitted 
photon for the radionuclides of interest and the corresponding linear attenuation coefficient 
and build up as a function of material thickness. Figure 13 presents a diagram showing the 
height of the liquid column’s effect on the angular response. (Chilton, Shultis, & Faw, 1984) 
 
 
 
 
 
 
Figure 13:  Detector response as a function of liquid column height 
Region of interest 
φ2 
φ1 
𝑝ℎ𝑜𝑡𝑜𝑛𝑠
𝑠𝑡𝑒𝑟𝑎𝑑𝑖𝑎𝑛 (𝜃1) − 𝑠𝑒𝑐
>
𝑝ℎ𝑜𝑡𝑜𝑛𝑠
𝑠𝑡𝑒𝑟𝑎𝑑𝑖𝑎𝑛 (𝜃2) − 𝑠𝑒𝑐
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Gamma camera detector efficiency. 
The NaI detector efficiency is photon energy dependent because the photoelectric effect 
dictates that lower energy photons are more likely to interact with the detector molecules 
and produce a detection event as compared to higher energy photons.  Therefore, the photon 
detection efficiency of gamma camera will need to be calibrated for its energy response.  The 
isotope Tc-99m (E=140 keV) was used to measure the energy dependent response of the 
gamma camera detector.  A urine sample container with a pre-measured activity of Tc-99m 
filled with 100 ml of water (as a surrogate for urine) was placed on the Lucite plastic sheet for 
Detector 2 and a one-minute count obtained.  An approximate 10,000 mm2 square-shaped 
region of interest (ROI) was drawn on the monitor where the specimen container was located.  
The total counts detected in the ROI were decay corrected from the beginning of the one-
minute count to the time of assay of the Tc-99m added to the specimen container.  The count 
was repeated three times and the average was calculated. 
Activity corrections for decay were determined using the general decay equation: 
𝐴(𝑡) = 𝐴0𝑒
−𝜆𝑡   (Eq. 31) 
Solving for A0: 
𝐴0 =
𝐴(𝑡)
𝑒−𝜆𝑡
    (Eq. 32) 
Where A0 is the activity corrected to the time of assay, 𝜆 is the decay constant for the 
radionuclide, and t is the elapsed time between time of assay and time the count was 
initiated. 
The efficiency was calculated using the following equation: 
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𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (
𝑐
ϒ
) =
𝐶𝑜𝑢𝑛𝑡 𝑅𝑎𝑡𝑒 (
𝑐
𝑠
)
𝐴(
𝑑
𝑠
)𝑌(
ϒ
𝑑
)
  (Eq. 33) 
The efficiency was determined for Tc-99m and compared to the MCNP calculated result to 
validate the MCNP model. 
Cross talk between regions of interest 
Counting multiple urine specimen containers concurrently on a single detector could cause 
photons emitted from one container to be detected into an adjacent container region (show 
an image of what you mean). The MCNP model was used to quantify the impact of crosstalk 
between adjacent containers and regions of interest for both the 3/8-inch and one-inch 
crystal for each of the radionuclides of interest. 
Monte Carlo Modeling 
The cylindrical volume source equations can be used to calculate the gamma camera detector 
response from the urine specimen container, but the presence of an attenuating medium, 
i.e., the urine, causes the formulation to be more complicated.  The formulation must be 
expressed analytically in terms of a geometrically elaborate integral requiring solution by 
numerical techniques.  For this reason, the container and gamma camera detector were 
modeled using the Monte Carlo processing software MCNP v 6.0.  The model was validated 
using radionuclides generally available in any nuclear medicine department.  Once the MCNP 
model was validated, it was then used to calculate detector response to each of the 
radionuclides of interest.  
MCNP was also used to calculate the detection efficiency of a one-inch thick sodium-iodide 
crystal for each of the radionuclides of interest.  The activity concentration for each 
49 
19-April-2019  
radionuclide was held constant, as was the urine specimen container geometry, and energy 
windows for the radionuclides and the detector efficiency calculated. Detector efficiency is 
expected to increase with the one-inch thick NaI crystal. 
Minimum Detectable Dose 
The standard nuclear medicine gamma camera (model # and manufacturer) was used to 
measure the concentration of specific radionuclides in urine at levels to determine whether 
they meet the committed effective dose-based clinical decision guidelines. 
To achieve this, background levels of radiation detected by a gamma camera, and its 
efficiency to detect the photons emitted by the radionuclides of interest were determined.  
This allowed the calculation of the Minimum Detectable Dose (MDD) for comparison to the 
clinical decision guideline dose levels.   
The minimum detectable dose is calculated using empirically derived Minimum Detectable 
Intake (MDI) equation (Anigstein, Olsher, & Loomis, 2010): 
𝑀𝐷𝐼 (𝐵𝑞) = (
2.71+4.65√𝐵𝑅𝑂𝐼
𝑌𝑛(
ϒ
𝑑
)𝐸𝑛(
𝑐
ϒ
)(
𝑉𝑠(𝑚𝑙)
1400𝑚𝑙
)
)    (Eq. 34) 
Where BROI is the background counts in the region of interest, Yn is the photon yield of energy 
Ei, and En is the efficiency of the detector for the nth radionuclide of interest, and Vs is the 
volume of urine in the specimen container. (Anigstein, Olsher, & Loomis, 2010) 
𝑀𝐷𝐷 (𝑆𝑣) =  𝑀𝐷𝐼(𝐵𝑞) × 𝑈𝐸𝐹 (
𝑆𝑣
𝐵𝑞
)   (Eq. 35) 
To obtain the MDD, the MDI is multiplied by the radionuclide’s UEF (Sv/Bq) at time t. Each 
UEF is a function of the chemical composition of the radioisotope and the route of entry.  UEF 
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dose conversion coefficients are divided into three types, Type F, Type M and Type S.  The 
types are based on the rapidity by which they are cleared from the body as compared to 
hypothetical elements of specific constant absorption rates.   
Type M is assumed when information is not available to assign an appropriate absorption 
type.  Type F material is used when the amount absorbed into blood 30 days after an acute 
intake is greater than the amount that would be absorbed with a constant rate of absorption 
with a 10-day half time.  Similarly, a Type S material would be selected when the amount 
absorbed into blood after 180 days after an acute intake is less than the amount that would 
be absorbed for a material with a constant rate of absorption into blood with a half time of 
700 days.  
III.  Results  
Background Determination 
The GE Hawkeye V3 Gamma Camera is a dual head design with a 9.5 mm thick NaI crystal 
with an active area dimension of 60 cm x 45.7 cm. The camera is equipped with 59 
photomultiplier tubes and includes software which allows for 4 discrete energy windows that 
can be set.  The uniformity of the detector surface response is checked daily using a cobalt-
57 flood source that covers the entire detector surface area. Corrections are made by 
adjusting the voltage applied to each individual photomultiplier tube to achieve a coefficient 
of variation less than ±5% across the surface of the detector. 
A protocol was selected for use in counting background and sample counts that allowed for 
a window to be easily set around the desired energy peak and the count time set manually.  
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Four three-minute background counts were performed with the energy window set on 140 
keV ±10%, and 5 distinct regions of the same pixel size on the detector surface were 
measured. The array of the ROI drawn on the monitor is shown in Figure 14. 
 
Figure 14: ROI array for background determination 
Table 5 presents the counting results for background for the defined regions of interest. 
Table 5: ROI Background Measurement 
ROI # 
Measurement 
1 CROI 
in 3 min 
Measurement 
2 CROI 
in 3 min 
Measurement 
3 CROI 
in 3 min 
Measurement 
4 CROI 
in 3 min 
 
Average 
(SD%) 
1 2589 2984 2653 2956 2796 (6) 
2 2520 2954 2660 2995 2782 (7) 
3 2723 3306 2682 3272 2996 (10) 
4 2570 3091 2716 3061 2856 (8) 
5 2349 2685 2408 2658 2525 (6) 
    Overall 2792 (7) 
 
Each ROI was approximately 10,000 mm2 and the count time was 3 minutes.  The average 
count in the ROI was 15.5 counts per second per 10,000 mm2 for an energy window of 140 
keV ± 10%. 
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Technitium-99m Validation of MCNP Model 
The specification for Tc-99m are presented in Table 6.  Table 7 presents the measurements 
results and efficiency of the gamma camera to detect the 140 keV gamma ray. 
Table 6: Specifications for Tc-99m 
Tc-99m half-life 6.007 hours 
Activity measured at t=0 
10.23 μCi 
(378,510 d/s) 
Energy Window 140 keV ± 10% 
Decay constant for Tc-99m 0.0019 min-1 
Tc-99m ϒ yield at 141 keV 0.89 ϒ/d 
 
Table 7: Tc-99m Activity Measurements in ROI 
ROI 1 
Time of 
count C ROI  Elapsed time 
Correction 
factor 
Corrected 
Activity 
Counts 
per sec 
1 15:26 2229770 c/m 1.00 min 0.99807868 2234062 37234 
2 15:31 2272968 c/m 6.00 min 0.98852734 2299348 38322 
3 16:05 2057220 c/m 40.00 min 0.92595786 2221721 37028 
       Average 37528 
The efficiency of the detector Tc-99m at 140 keV ±10% for a 100 ml urine specimen geometry 
was: 
𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (
𝑐
ϒ
) =
𝐶𝑜𝑢𝑛𝑡 𝑅𝑎𝑡𝑒 (
𝑐
𝑠)
𝐴 (
𝑑
𝑠) 𝑌 (
ϒ
𝑑)
=  
37528 − 15
(378,510)(0.89)
= 0.111 
𝑐
𝛾
 𝑜𝑟 11.1%   
The detector efficiency for the urine specimen geometry on the Hawkeye Gamma Camera 
was modeled in MCNP using the parameters in Table 8. 
Table 8: MCNP Input Parameters for comparison to experimental results 
Input parameter Value 
Urine vol. (ml) 100 
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Activity (Bq) 1 
Energy window (keV) 126 – 156 
Detector thickness (mm) 10 
Acrylic cover thickness (mm) 6 
Detector size (mm) 400 x 400 
Region of Interest size (mm) 100 x 100 
Air gap from cover to detector (mm) 20 
# of histories 1x107 
 
The efficiency for Tc-99m using MCNP for the given input parameters was calculated as 
12.0%.  The difference between experimental and theoretical efficiencies was:  
11.1% − 12.0%
12.0%
= ± 8% 
MCNP derived efficiencies for radionuclides of interest  
MCNP was used to calculate the efficiency of the Hawkeye Gamma Camera and urine 
specimen sample container geometry as a function of photon energy. Table 9 and Figure 15 
present the results of the MCNP model for both the 3/8-inch (1 cm) NaI crystal and a one-
inch (2.54 cm) crystal, respectively.    
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Table 9: Detector efficiencies for photon energy ranges from 75 keV to 1400 keV 
Energy 
(MeV) 
Energy 
(keV) 
3/8-inch (1 cm) 
Thick crystal 
1-inch (2.54 cm) 
Thick crystal 
0.0750 75 12.6% 12.6% 
0.1000 100 12.8% 12.9% 
0.1250 125 12.5% 12.8% 
0.1500 150 11.5% 12.5% 
0.1750 175 10.1% 12.0% 
0.2000 200 8.7% 11.4% 
0.2250 225 7.4% 10.6% 
0.2500 250 6.3% 9.7% 
0.2750 275 5.4% 8.9% 
0.3000 300 4.7% 8.2% 
0.3250 325 4.1% 7.5% 
0.3500 350 3.6% 6.9% 
0.3750 375 3.2% 6.4% 
0.4000 400 2.9% 5.9% 
0.4250 425 2.6% 5.5% 
0.4500 450 2.4% 5.1% 
0.4750 475 2.2% 4.8% 
0.5000 500 2.0% 4.5% 
0.5500 550 1.7% 4.1% 
0.6000 600 1.5% 3.7% 
0.6500 650 1.3% 3.4% 
0.7000 700 1.2% 3.1% 
0.7500 750 1.1% 2.9% 
0.8000 800 1.0% 2.7% 
0.8500 850 0.9% 2.5% 
0.9000 900 0.9% 2.4% 
0.9500 950 0.8% 2.2% 
1.0000 1000 0.8% 2.1% 
1.0500 1050 0.7% 2.0% 
1.1000 1100 0.7% 1.9% 
1.1500 1150 0.6% 1.9% 
1.2000 1200 0.6% 1.8% 
1.2500 1250 0.6% 1.7% 
1.3000 1300 0.5% 1.6% 
1.3500 1350 0.5% 1.6% 
1.4000 1400 0.5% 1.5% 
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Figure 15: Gamma Energy versus MCNP-derived Detection Efficiency for the 3/8-inch (1 cm) 
and one-inch (2.54 cm) NaI crystal  
Table 10 presents the detector efficiency for the radionuclides of interest determined using 
the MCNP model for the Hawkeye Gamma Camera (1 cm crystal thickness) and 100 ml urine 
specimen geometry. 
Table 10: MCNP-derived efficiencies for Radionuclides of Interest for a 1 cm thick NaI crystal 
Radionuclide 
Energy Range (Peak 
keV ±10%) 
Efficiency (%) 
Cobalt-60 1056 - 1466 0.8 
Iodine-131 328 - 401 2.9 
Cesium-137 595 - 728 1.4 
Iridium-192 267 - 348 3.1 
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Figure 16: Detection Efficiency vs Sample Size for 1 cm NaI Crystal 
 
Figure 17: Detection Efficiency vs Sample Size for 2.54 cm NaI Crystal 
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Table 11 presents detector efficiency for radionuclides of interest with specified energy 
windows at increasing urine volume from 10 ml to 250 ml for a 3/8-inch (1 cm) and 1-inch 
(2.54 cm) thick NaI crystal. 
Table 11:  Calculated detector efficiency for radionuclides of interest with energy windows as 
a function of urine sample volume for a one-inch (2.54 cm) thick NaI crystal 
  
 Vol. 
 (ml) 
(1056-1466 keV) (126 - 156 keV) (328 - 401 keV) (595 -728 keV) (267 -348 keV) 
Cobalt-60 Tc-99m Iodine-131 Cesium-137 Iridium-192 
1 cm 2.54 cm 1 cm 2.54 cm 1 cm 2.54 cm 1 cm 2.54 cm 1 cm 2.54 cm 
10 1.2% 3.1% 19.5% 20.4% 4.7% 8.8% 2.2% 5.2% 4.9% 8.4% 
20 1.1% 2.9% 18.4% 19.3% 4.4% 8.3% 2.0% 5.0% 4.7% 8.0% 
30 1.1% 2.8% 17.4% 18.3% 4.1% 7.8% 1.9% 4.7% 4.4% 7.6% 
40 1.0% 2.6% 16.5% 17.3% 3.9% 7.4% 1.8% 4.5% 4.2% 7.2% 
50 1.0% 2.5% 15.7% 16.4% 3.7% 7.1% 1.7% 4.2% 4.0% 6.8% 
60 0.9% 2.4% 14.9% 15.6% 3.5% 6.7% 1.6% 4.0% 3.8% 6.5% 
70 0.9% 2.3% 14.2% 14.9% 3.3% 6.4% 1.6% 3.9% 3.6% 6.2% 
80 0.8% 2.2% 13.5% 14.2% 3.2% 6.1% 1.5% 3.7% 3.4% 6.0% 
90 0.8% 2.1% 12.9% 13.6% 3.0% 5.9% 1.4% 3.5% 3.3% 5.7% 
100 0.8% 2.0% 12.4% 13.0% 2.9% 5.6% 1.4% 3.4% 3.1% 5.5% 
110 0.7% 2.0% 11.9% 12.5% 2.8% 5.4% 1.3% 3.2% 3.0% 5.3% 
120 0.7% 1.9% 11.4% 12.0% 2.7% 5.2% 1.2% 3.1% 2.9% 5.1% 
130 0.7% 1.8% 10.9% 11.5% 2.6% 5.0% 1.2% 3.0% 2.8% 4.9% 
140 0.7% 1.7% 10.5% 11.1% 2.5% 4.8% 1.1% 2.9% 2.7% 4.7% 
150 0.6% 1.7% 10.1% 10.7% 2.4% 4.6% 1.1% 2.8% 2.6% 4.5% 
160 0.6% 1.6% 9.8% 10.3% 2.3% 4.5% 1.1% 2.7% 2.5% 4.4% 
170 0.6% 1.6% 9.4% 9.9% 2.2% 4.3% 1.0% 2.6% 2.4% 4.2% 
180 0.6% 1.5% 9.1% 9.6% 2.1% 4.2% 1.0% 2.5% 2.3% 4.1% 
190 0.6% 1.5% 8.8% 9.3% 2.1% 4.0% 1.0% 2.4% 2.2% 4.0% 
200 0.5% 1.4% 8.5% 9.0% 2.0% 3.9% 0.9% 2.4% 2.2% 3.8% 
210 0.5% 1.4% 8.2% 8.7% 1.9% 3.8% 0.9% 2.3% 2.1% 3.7% 
220 0.5% 1.4% 8.0% 8.4% 1.9% 3.7% 0.9% 2.2% 2.0% 3.6% 
230 0.5% 1.3% 7.7% 8.2% 1.8% 3.6% 0.8% 2.2% 2.0% 3.5% 
240 0.5% 1.3% 7.5% 7.9% 1.8% 3.5% 0.8% 2.1% 1.9% 3.4% 
250 0.5% 1.3% 7.3% 7.7% 1.7% 3.4% 0.8% 2.0% 1.9% 3.3% 
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Crosstalk between adjacent regions of interest 
The cross talk from one ROI to another for the fixed sample geometry was calculated for each 
radionuclide of interest using MCNP v6.0. The positioning of ROI A with respect to ROI B is 
presented in Figure 18. The results are presented in Figures 19 through 22.  The concentration 
of activity was held constant, the ROI area is defined as 10 cm x 10 cm, and the solution 
volume varied from 30, 60, to 90 ml.  The cross talk between regions of interest was also 
calculated as the distance between them ranged from 0 cm (touching) to 19.5 cm for the 3/8-
inch and one-inch NaI crystals.  The results are presented for each radionuclide in Figures 21 
through 25. 
 
 
 
 
Figure 18:  Detector active surface area with ROI 
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Figure 19: Tc-99m Percent Count in ROI B from Sample in ROI A for Sample volume of 30, 60 
and 90 ml 
 
 
Figure 20: Tc-99m Percent Count in ROI B from Sample in ROI A for volume of 30, 60 and 90 
ml 
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Figure 21: Cs-137 Percent Count in ROI B from Sample in ROI A for volume of 30, 60 and 90 
ml 
 
Figure 22: Cobalt-60 Percent Count in ROI B from Sample in ROI A for volume of 30, 60 and 
90 ml 
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Figure 23:  Cobalt-60 Crosstalk (%) for Separation Distances of ROI's from 0 - 19.5 cm 
 
Figure 24:  Iodine-131 Crosstalk for Separation Distances of ROI's for Separation from 0 - 
19.5 cm 
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Figure 25: Cesium-137/Barium-137m Crosstalk (%) for Separation Distances of ROI's from 0 - 
19.5 cm 
 
  
 
 
 
 
Figure 26:  Technitium-99m Crosstalk for Separation Distances of ROI's from 0 - 19.5 cm 
Figure 26:  Technitium-99m Crosstalk for Separation Distances of ROI's from 0 - 19.5 cm 
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Figure 27:  Iridium-192 Crosstalk (%) for Separation Distances of ROI's from 0 - 19.5 cm 
Minimum Detectable Intake 
The MDI is calculated using the following equation which is based on the background count 
rate in the region of interest: 
𝑀𝐷𝐼 (𝐵𝑞) = (
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𝑑
)𝐸𝑛(
𝑐
ϒ
)(
𝑉𝑠(𝑚𝑙)
1400𝑚𝑙
)
)  (Eq. 8) 
The background counts in the region of interest for different energy windows selected on 
the gamma camera and the average was presented in Table 5.  The background radiation 
measurements for the gamma camera at specific energies using three regions of interest of 
similar size are presented in Table 12. 
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Table 12: Background measurements at select gamma energy windows. 
Energy 
Window 
(keV) 
Energy 
peak 
center 
(keV) 
Measurement 
1 CROI 
in 3 min 
Measurement 
2 CROI 
in 3 min 
Measurement 
3 CROI 
in 3 min 
Average 
(Counts/sec) 
(SD%) 
45 - 55 50 1410 1579 2513*  8.3 (8) 
90 - 110 100 19745*  10988 11698 63 (4) 
135 - 165 150 3467 3492 4218 20.7 (11) 
225 - 275 250 2516 2492 2551 14.0 (1) 
 364 364 1408 1441 1440 7.9 (1) 
* Background value affected by patient being scanned in adjacent room. Data point not used 
to calculate average. 
The distribution of background counts as a function of energy for the GE Hawkeye Gamma 
Camera is presented in Figure 28. 
 
Figure 28: Background photon energy distribution for the GE Hawkeye V3, 3/8-inch NaI 
crystal 
 
Table 13 presents the data for the Radionuclides of Interest used to calculate the MDI, the 
MCNP-derived efficiency, photon yield, value of the background detection events at the 
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radionuclide energy and the resulting MDI. All values are for a sample of 100 ml and a 1 cm 
thick NaI crystal. 
Table 13: MDI and calculation parameters for the radionuclides of interest at 100 ml and 1 
cm thick NaI crystal 
Radio- 
nuclide 
Energy 
(keV) 
Efficiency 
(c/ϒ) 
Yield 
(ϒ/d) 
Background 
(c/s) 
MDI    
(Bq) 
Co-60 1025 0.008 2 7.9 13807 
I-131 364 0.029 0.815 7.9 9347 
Cs-137 662 0.014 0.851 7.9 18543 
Ir-192 316 0.031 0.82 10 9591 
 
Minimum detectable dose (MDD) 
Minimum detectable dose (MDD) for a 100 ml sample at time t post incident was calculated 
by multiplying the MDI by the UEF (Sv/Bq).  The results of the MDD calculations are presented 
in Tables 14   through 17. 
𝑀𝐷𝐷 (𝑆𝑣) =  𝑀𝐷𝐼(𝐵𝑞) × 𝑈𝐸𝐹 (
𝑆𝑣
𝐵𝑞
)  (Eq. 9) 
Table 14: MDD for cobalt-60 (t) days post incident for a 100 ml sample 
Cobalt-60 MDD (Sv) 
Days Type F Type M Type S 
1 1.79E-03 1.28E-02 1.28E+00 
2 4.28E-03 3.04E-02 3.04E+00 
3 7.59E-03 5.25E-02 5.38E+00 
4 1.12E-02 7.32E-02 7.59E+00 
5 1.52E-02 9.53E-02 1.01E+01 
6 1.93E-02 1.17E-01 1.27E+01 
7 2.35E-02 1.38E-01 1.52E+01 
8 2.90E-02 1.66E-01 1.79E+01 
9 3.59E-02 1.93E-01 2.21E+01 
10 4.14E-02 2.07E-01 2.49E+01 
15 7.59E-02 3.04E-01 3.87E+01 
30 2.07E-01 4.97E-01 7.04E+01 
45 4.14E-01 6.35E-01 9.11E+01 
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60 6.63E-01 7.32E-01 1.04E+02 
90 1.09E+00 9.11E-01 1.17E+02 
180 2.49E+00 1.66E+00 1.52E+02 
365 6.35E+00 4.83E+00 2.07E+02 
 
Table 15: MDD for iodine-131 (t) days post incident for a 100 ml sample 
Iodine-131 MDD (Sv) 
Days Type F Type M Type S 
1 2.71E-04 3.64E-04 1.69E-03 
2 1.36E-03 1.10E-03 4.57E-03 
3 1.02E-02 7.62E-03 3.22E-02 
4 8.05E-02 4.07E-02 1.86E-01 
5 3.39E-01 9.32E-02 4.66E-01 
6 4.91E-01 1.19E-01 6.35E-01 
7 4.83E-01 1.36E-01 7.37E-01 
8 4.66E-01 1.52E-01 8.22E-01 
9 4.57E-01 1.69E-01 9.32E-01 
10 4.66E-01 1.86E-01 1.02E+00 
15 5.59E-01 2.88E-01 1.61E+00 
30 1.69E+00 1.02E+00 5.68E+00 
45 6.52E+00 4.07E+00 2.12E+01 
60 2.54E+01 1.61E+01 8.22E+01 
90 4.07E+02 2.54E+02 1.19E+03 
 
Table 16: MDD for cesium-137 (t) days post incident for a 100 ml sample 
Cesium-137 MDD (Sv) 
Days Type F Type M Type S 
1 6.79E-03 2.40E-02 1.20E+00 
2 1.44E-02 3.79E-02 1.88E+00 
3 2.20E-02 6.19E-02 3.00E+00 
4 3.00E-02 8.39E-02 4.19E+00 
5 3.39E-02 9.98E-02 4.99E+00 
6 3.79E-02 1.12E-01 5.59E+00 
7 4.19E-02 1.22E-01 5.99E+00 
8 4.59E-02 1.30E-01 6.39E+00 
9 4.79E-02 1.36E-01 6.79E+00 
10 4.79E-02 1.40E-01 6.99E+00 
15 5.39E-02 1.54E-01 7.79E+00 
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30 6.19E-02 1.74E-01 8.79E+00 
45 6.99E-02 1.94E-01 9.98E+00 
60 7.99E-02 2.20E-01 1.10E+01 
90 1.02E-01 2.60E-01 1.36E+01 
180 2.20E-01 4.79E-01 2.40E+01 
365 9.78E-01 1.74E+00 6.99E+01 
 
Table 17: MDD for iridium-192 (t) days post incident for a 100 ml sample 
Iridium-192 MDD (Sv) 
Days F M S 
1 3.80E-04 5.06E-03 1.45E-01 
2 1.96E-03 2.15E-02 6.26E-01 
3 3.10E-03 3.48E-02 1.08E+00 
4 4.05E-03 4.43E-02 1.33E+00 
5 5.00E-03 5.19E-02 1.64E+00 
6 5.95E-03 5.95E-02 1.90E+00 
7 6.96E-03 6.96E-02 2.15E+00 
8 7.59E-03 6.96E-02 2.40E+00 
9 8.86E-03 7.59E-02 2.59E+00 
10 9.49E-03 8.22E-02 2.85E+00 
15 1.39E-02 1.08E-01 3.80E+00 
30 3.10E-02 1.71E-01 6.33E+00 
45 5.06E-02 2.21E-01 8.86E+00 
60 6.96E-02 2.78E-01 1.08E+01 
90 1.20E-01 4.18E-01 1.52E+01 
180 4.36E-01 1.33E+00 3.86E+01 
365 4.74E+00 1.39E+01 2.59E+02 
 
IV.  Discussion 
The results for the validation of the MCNP model demonstrated that the model was 
sufficiently accurate to calculate the efficiency of the Hawkeye gamma camera and urine 
specimen container geometry. MCNP calculated the detector efficiency as 12% as shown in 
Figure 25.  Measurement of the detector efficiency was 11.1% for a difference of 8%. The 
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activity of Tc-99m (140 keV) was measured using the Capintec well counter; however, the 
measurement of 10.23 μCi of Tc-99m is the minimum of the calibrated range of the Capintec.  
Therefore, this contributed to the difference between the measured detector efficiency and 
MCNP calculated value.  Each MCNP derived detection efficiency was based on 1 107 
histories for an uncertainty of <0.1%.  Notwithstanding the likely inaccuracy in measured Tc-
99m activity, the validation results are sufficiently accurate and the MCNP model is 
considered accurate. The model was used to calculate detector efficiencies for the 3/8-inch 
(1 cm) and one-inch (2.54 cm) thick NaI detectors. 
For each radionuclide of interest, background values for the predominant photon energy 
window was used to calculate the Minimum Detectable Concentration (MDC), which was 
converted to Minimum Detectable Intake (MDI), and the Minimum Detectable Dose (MDD) 
for Types F, M and S materials.  For the counting geometry, background values were 
measured for the energy windows at 50, 100, 150, 250 and 364 keV.  This involved placing a 
urine specimen container holding 100 ml of water with no radioactivity introduced on the 
center of the detector, a three-minute count initiated, and a 10 cm x 10 cm ROI used to 
quantify the number of detection events expressed as counts per second.  Background values 
are used to calculate MDI as described in Equation 8.  These values were used in the MDC 
equation along with the MCNP derived efficiency for the predominant photon energy of the 
radionuclide of interest, with the volume normalized to 1.4 liters (reference person daily 
urinary excretion volume). The value was divided by the radionuclide specific urinary 
excretion fraction to determine the radionuclide intake and subsequent MDD, as a function 
of the time elapsed between the incident (i.e., intake) and the urine sample collection.  If the 
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time elapsed between sample collection and analysis is a significant fraction of the 
radionuclide half-life, a decay correction calculation must be applied.  The results for these 
calculations are described below. 
Cobalt-60  
Figure 27 shows for cobalt-60, the maximum time post incident that a committed dose of 20 
mSv is detectable in urine specimens counted on the Hawkeye gamma camera is 
approximately 6 days for Type F, 1 day for Type M, and is undetectable for Type S. For a MDD 
of 250 mSv, the time post incident that a dose is detectable is 30 days for Type F, 10 days for 
Type M and is undetectable for Type S. Although the detection efficiency for the gamma 
camera is much lower due to the higher energy photons, the background is comparably less 
so a window established to detect photons with an average of 1025 keV can provide sufficient 
sensitivity to positively detect intakes resulting in a 20 mSv committed dose or less.  The MDD 
was calculated based on a background value of 7.9 counts per second, determined for 364 
keV, which is considered conservative based on the background spectrum versus photon 
energy displayed by the gamma camera software.  
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Figure 29: MDD for Cobalt-60 (Type F, S, M) days post incident 
The detector efficiency as a function of urine sample volume containing Cobalt-60 (as 
presented in Table 11) assuming a constant concentration ranged from 1.2% for 10 ml sample 
volume to 0.5% for a 250 ml sample volume, and an efficiency of 0.7% for 100 ml for the 3/8-
inch crystal.  This resulted in a 35.3 % reduction for a sample volume of 100 ml.  The reduced 
efficiency was due to self-attenuation of the photons in the sample as well as photon 
emissions from upper layers of the solution emitted in the direction of the detector falling 
outside the ROI. The one-inch crystal ranged from 3.1% for a 10 ml urine sample to 1.3% for 
a 250 ml sample, with 2% at 100 ml.  This resulted in a 35% reduction for a sample volume of 
100 ml.  The difference in efficiency between the two crystals for the 100 ml sample is due to 
the higher detection efficiency for the 1025 keV photons in the one-inch crystal. 
The contribution of counts from a urine sample in ROI 1 to the counts of a sample in ROI 2 
was determined for separation distances ranging from 0 cm (ROIs touching) to 19.5 cm (as 
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presented in Figure 21). The contribution ranged from approximately 29.3% for ROIs that are 
immediately adjacent (touching) to 2.3% at a separation of 19.5 cm for the 3/8-inch crystal.  
The contribution ranged from approximately 30.9% for ROIs that are immediately adjacent 
(touching) to 2.1% at a separation of 19.5 cm for the one-inch crystal. 
Iodine-131 
Figure 28 shows for iodine-131 the maximum time post incident that a committed dose of 20 
mSv is detectable in urine specimens counted on the Hawkeye gamma camera is 
approximately 3 days for Type F, 3 days for Type M, and 2 days for Type S. For a MDD of 250 
mSv, the time post incident that a dose is detectable is 4 days for Type F, 10 days for Type M 
and 4 days for Type S.  These values are consistent with known excretion of iodine-131 in 
urine.  For a reference person, approximately 80% of iodine-131 as sodium iodide is excreted 
in urine within 48 hours. (ICRP, 2017) 
 
Figure 30: MDD for Iodine-131 (Type F, S, M) days post incident 
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The detector efficiency as a function of urine sample volume containing Iodine-131 (see Table 
11) assuming a constant concentration ranged from 4.7% for 10 ml sample volume to 1.7% 
for a 250 ml sample volume, and an efficiency of 2.9% for 100 ml for the 3/8-inch crystal.  This 
resulted in a 36 % reduction for a sample volume of 100 ml.  The reduced efficiency was due 
to self-attenuation of the photons in the sample as well as photon emissions from upper 
layers of the solution emitted in the direction of the detector falling outside the ROI. The one-
inch crystal ranged from 8.8% for a 10 ml urine sample to 3.4% for a 250 ml sample, with 5.6% 
at 100 ml.  This resulted in a 33.3% reduction for a sample volume of 100 ml.  The difference 
in efficiency between the two crystals for the 100 ml sample is due to the higher detection 
efficiency for the 360 keV photons in the one-inch crystal. 
The contribution of counts from a urine sample in ROI 1 to the counts of a sample in ROI 2 
was determined for separation distances ranging from 0 cm (ROIs touching) to 19.5 cm (See 
Figure 22). The contribution ranged from approximately 26.5% for ROIs that are immediately 
adjacent (touching) to 1.4% at a separation of 19.5 cm for the 3/8-inch crystal.  The 
contribution ranged from approximately 26% for ROIs that are immediately adjacent 
(touching) to 1% at a separation of 19.5 cm for the one-inch crystal.  
Cesium-137 
Figure 29 shows for cesium-137 the time post incident that a committed dose of 20 mSv is 
detectable in urine specimens counted on the Hawkeye gamma camera is approximately 2 
days for Type F, and is undetectable for Types M and S. For a MDD of 250 mSv, the time post 
incident that a dose is detectable is 180 days for Type F, 610 days for Type M and I 
undetectable for Type S. Although the detection efficiency for the gamma camera is much 
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lower due to the higher energy photons at 662 keV, the background is comparably less so a 
window established to detect photons with an average of 662 keV can provide sufficient 
sensitivity to positively detect intakes resulting in a 20 mSv committed dose or less.  The MDD 
was calculated based on a background value of 7.9 counts per second, determined for 364 
keV, which is considered conservative based on the background spectrum versus photon 
energy displayed by the gamma camera software. 
 
Figure 31: MDD for Cesium-137 (Type F, S, M) days post incident 
The detector efficiency as a function of urine sample volume containing Cesium-137 (see 
Table 11) assuming a constant concentration ranged from 2.2% for 10 ml sample volume to 
0.8% for a 250 ml sample volume, and an efficiency of 1.4% for 100 ml for the 3/8-inch crystal.  
This resulted in a 35 % reduction for a sample volume of 100 ml.  The reduced efficiency was 
due to self-attenuation of the photons in the sample as well as photon emissions from upper 
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layers of the solution emitted in the direction of the detector falling outside the ROI. The one-
inch crystal ranged from 5.2% for a 10 ml urine sample to 2% for a 250 ml sample, with 3.4% 
at 100 ml.  This resulted in a 35% reduction for a sample volume of 100 ml.  The difference in 
efficiency between the two crystals for the 100 ml sample is due to the higher detection 
efficiency for the 661 keV photons in the one-inch crystal. 
The contribution of counts from a urine sample in ROI 1 to the counts of a sample in ROI 2 
was determined for separation distances ranging from 0 cm (ROIs touching) to 19.5 cm (See 
Figure 23). The contribution ranged from approximately 28.3% for ROIs that are immediately 
adjacent (touching) to 1.9% at a separation of 19.5 cm for the 3/8-inch crystal.  The 
contribution ranged from approximately 28.8% for ROIs that are immediately adjacent 
(touching) to 1.5% at a separation of 19.5 cm for the one-inch crystal. 
Iridium-192 
Figure 30 shows for iridium-192 the time post incident that a committed dose of 20 mSv is 
detectable in urine specimens counted on the Hawkeye gamma camera is approximately 20 
days for Type F, one day for Type M, and is not detectable for Type S. For a MDD of 250 mSv, 
the time post incident that a dose is detectable is 90 days for Type F, 45 days for Type M and 
one day for Type S. 
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Figure 32: MDD for Iridium-192 (Type F, S, M) days post incident 
The detector efficiency as a function of urine sample volume containing Iridium-192 (see 
Table 11) assuming a constant concentration ranged from 4.9% for 10 ml sample volume to 
1.9% for a 250 ml sample volume, and an efficiency of 3.1% for 100 ml for the 3/8-inch crystal.  
This resulted in a 37 % reduction for a sample volume of 100 ml.  The reduced efficiency was 
due to self-attenuation of the photons in the sample as well as photon emissions from upper 
layers of the solution emitted in the direction of the detector falling outside the ROI. The one-
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at 100 ml.  This resulted in a 35% reduction for a sample volume of 100 ml.  The difference in 
efficiency between the two crystals for the 100 ml sample is due to the higher detection 
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Figure 25). The contribution ranged from approximately 26.7% for ROIs that are immediately 
adjacent (touching) to 1.3% at a separation of 19.5 cm for the 3/8-inch crystal.  The 
contribution ranged from approximately 22.7% for ROIs that are immediately adjacent 
(touching) to 0.8% at a separation of 19.5 cm for the one-inch crystal. 
Volume Throughput 
In the event of an incident, the number of urine specimens that could be analyzed using the 
method in this dissertation is estimated as follows. 
The detector dimensions are 60 x 40 cm.  An array of twenty-four 10 x 10 cm regions of 
interest can be assembled on the detector surface and can be analyzed in a single 3-minute 
count.  Assuming a tray of 24 urine specimen containers can be placed on the detector, 
analyzed, and replaced every 10 minutes, a total of 144 samples can be analyzed per hour.  
Technologists could, therefore, theoretically analyze a total of 1,152 samples in a single 8-
hour shift using a single gamma camera.   
This arrangement of sample containers on the detector surface will result in photons emitted 
from one sample being attributed to the sample in the adjacent ROI.  The crosstalk between 
adjacent (touching) ROIs was consistent at 26% ±3%.  The impact of this scenario is discussed.  
A sample containing significant activity is detected by the gamma camera detector.  The 
samples immediately adjacent to the sample also exhibit activity but at a much lower activity.  
The adjacent samples, therefore, may or may not possess activity.  The central sample 
exhibiting the highest count should be removed from the tray and the remaining samples 
counted once again.  
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Samples containing a higher volume of urine will see a commensurate reduction in detector 
efficiency depending on photon energy.  However, smaller volumes of urine containing low 
activities may be missed because the gross activity is low.  Therefore, the selected volume of 
100 ml for a urine sample is a compromise for the tradeoff between sample volume and 
detector efficiency. 
V.  Limitations 
The MDD is based on several limiting variables.  A description of the limitations follows.  The 
urine specimen container used for the sample geometry used in this study is only one of many 
available.  The detection efficiency is related to the cylindrical volume of the container and 
the quantity of medium.  As the height of the cylinder increases, the decays occurring in the 
upper portion of the column height have a lower probability of being detected due to 
attenuation in the medium and the increase in distance from the detector surface.  Since a 
region of interest (ROI) of 10 cm x 10 cm was selected, any decays that result in the photon 
interacting with the detector outside the ROI will not contribute to the sample count.  
Measurements of the number of counts that are detected was modeled in MCNP as a 
function of height of the medium in the sample container geometry and increasing area of 
the ROI and the concentration of radionuclide held constant.  The detection efficiency was 
found to be a function of photon energy, height of liquid in the column and the area of the 
ROI.  A higher efficiency could be obtained if a larger ROI was selected, but this reduces the 
number of sample containers that could be counted at the same time.  For these reasons, a 
ROI of 10 cm x 10 cm, and a sample volume of 100 ml in the specific model of sterile urine 
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specimen container provided the optimal counting efficiency while maintaining the capability 
for high throughput bioanalyses. 
The Hawkeye gamma camera was the camera available at the hospital where this research 
was conducted.  There are many gamma cameras available that may offer improved counting 
efficiency, detector size, and counting geometry.  The parameters that were critical to proper 
modeling of the counting geometry for input to the MCNP model included the thickness of 
the plastic cover inserted over the detector, the measurement of the air gap between the 
plastic cover and the surface of the detector.  These values were measured using a handheld 
scale.  Inaccuracies in these measurements would lead to differences between measured and 
modeled detection efficiencies which may be the reason for the 8% difference in measured 
versus modeled detection efficiency for Tc-99m.  However, this difference was considered 
adequate for validation of the model, and the MCNP derived values of detection efficiencies 
were then used in the determination of radionuclide specific MDDs. 
The MDD is based on the number of counts that comprise background radiation in which the 
environment the camera is located.  During the measurements of background for various 
energy windows it was noted that radioactivity injected into patients in nearby rooms altered 
the background values measured.  This results in the removal of two data points from 
background determinations.  More background measurements for averaging purposes would 
have been helpful but the gamma camera was actively used for clinical purposes and 
impacting patient care was not an option.  Additionally, use of the clinical equipment required 
the presence of nuclear medicine staff which also limited the availability of time of use.  
However, the spectrum of background radiation was available as a display and was used to 
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verify the background count rates and conditions.  The highest energy that could be measured 
using available radioisotope settings on the Hawkeye was that for Iodine-131 or 364 keV.  It 
is possible to allow higher energies to be measured on the Hawkeye but would have required 
reconfiguring the software.  This was not done.  Instead, the background value measured for 
the 364 keV ± 10% window was used for the radioisotopes that produce photons greater than 
that for Iodine-131.  The background spectrum supported this approach and was considered 
conservative as the number of background counts were lower for higher energy photons.   
It is also possible to establish 4 energy windows for a single sample count on the Hawkeye.  It 
is therefore possible to select multiple photon energy windows for a sample count that would 
increase detection efficiency.  However, for the purpose of this dissertation a single energy 
peak for the predominant photon was selected.   
The use of 100 ml of urine in the sample counting geometry is another limitation.  The ICRP 
method used to calculate intake and subsequently, dose, is based on a 24-hour void 
normalized to a reference person volume of 1.4 liters of urinary excretion per day.  The use 
of smaller samples is allowed in the ICRP method provided the volume correction is made as 
this is what the intake dose coefficients were based.  If smaller volumes are collected for 
analysis they recommend that the sample be the first void of the day. 
The error in the dose coefficients is a limitation in the estimation of intake.  The ICRP models 
are based on studies on animal and human measurements.  As such, the results are averaged 
and are used to represent a single individual.  For some radioisotopes such as Iodine-131, the 
human biokinetic model is very well known as this radioisotope has been used clinically in the 
treatment of thyroid conditions for several decades.  Data for the other radioisotopes used 
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in this dissertation are also fairly well known as they are available in the nuclear industry and 
human contaminations have occurred. 
VI.  Conclusions 
This study has shown that the Hawkeye gamma camera can be used to measure radioactivity 
in urine specimens for the estimation of intake values and subsequent committed effective 
dose for Type F and M photon emitting radioisotopes with sufficient accuracy to meet dose-
based detection limits of 20 and 250 mSv. 
Additionally, the use of the gamma camera allows multiple samples to be analyzed at the 
same time thus allowing large number of samples to be analyzed in a relatively short amount 
of time.  In the event of a large scale incident involving the release of radioisotopes, the 
gamma camera can be used effectively to screen large numbers of individuals in a population 
to identify those with an intake of clinical significance.  In addition, the use of the gamma 
camera in a hospital setting addresses CLIA concerns that biological samples be analyzed in 
an appropriate environment. 
Although MDD is a function of detector efficiency, and detector efficiency is affected by 
sample volume, the selected volume of 100 ml appears to be a logical compromise between 
the total activity in a sample that can be detected, and the loss in signal due to self-
attenuation by the sample media.  
Using an array of 24 samples for simultaneous counting may result in additional samples 
being incorrectly identified as containing activity when they do not, the presence of a sample 
with high activity can be removed and the remaining samples recounted.   
81 
19-April-2019  
If a 1-inch (2.54 cm) thick NaI crystal gamma camera is used, the detection efficiency is 
increased for all radionuclides of interest, and lower limits of detection and MDD are possible. 
In conclusion, the use of the gamma camera for radiobioassay of urine specimens is 
sufficiently sensitive to detect intakes below the dose-based clinical decision guidelines 
provided samples are collected early after the suspected intake.  Gamma cameras are a 
standard device used in nuclear medicine departments throughout the world, are operated 
by trained staff and in a CLIA setting.  The use of the gamma camera for high volume 
throughput radiobioassay is also it was estimated that 1,152 urine samples could be analyzed 
in an 8-hour shift, and three times this number if operated continuously over a 24-hour 
period.   
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